The Data Safety Monitoring Board (DSMB) says Moderna has met 94.5 per cent efficacy in the pre-specified criteria of their vaccine.
The result came a week after Pfizer’s vaccine results, New Medical Life Sciences reported.
US Biotechnology Company, Moderna has been working on a vaccine to potentially treat COVID-19 since mid-January, and has released their phase three results for their mRNA-1273 vaccine.
According to Moderna, the early phase three clinical trial results of COVID-19 vaccine are nearly 95 per cent successful.
The study, known as the COVE study, has enrolled more than 30,000 participants in the US and has been conducted in collaboration with National Institutes of Health (NIH), Biomedical Advanced Research and Development Authority (BARDA), National Institute of Allergy and Infectious Diseases (NIAID).
Half of the 30,000 participants were given two doses of the vaccine while the other half received a placebo.
The first interim analysis was performed on 95 cases, of which in the placebo group there were 90 cases of COVID-19 compared to 5 cases observed in the mRNA-1273 group. This resulted in a vaccine efficacy of 94.5% (p < 0.0001).
The secondary endpoint saw 11 severe cases of COVID-19 in the first interim analysis, however, all 11 cases were in the Placebo group.
The interim analysis also reported no significant safety concerns and reported that the vaccine was well tolerated with the majority of adverse reactions being mild to moderate in their severity.
The data are still subject to change due to the ongoing analysis of further data and their final results.
